Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
119,747,899
-
Total 13F shares
-
31,697,688
-
Share change
-
+125,230
-
Total reported value
-
$95,408,027
-
Price per share
-
$3.01
-
Number of holders
-
44
-
Value change
-
+$377,390
-
Number of buys
-
21
-
Number of sells
-
10
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q4 2025
As of 31 Dec 2025,
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by
44 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,697,688 shares.
The largest 10 holders included
BML Capital Management, LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, ACADIAN ASSET MANAGEMENT LLC, Connor, Clark & Lunn Investment Management Ltd., DEUTSCHE BANK AG\, Three Bridge Wealth Advisors, LLC, GOLDMAN SACHS GROUP INC, JPMORGAN CHASE & CO, and Aisling Capital Management LP.
This page lists
45
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.